All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

FDA-&-EMA-New-Drug Approvals(Mid-2020 Recap)-insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Implicit Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Chinaplas 2020

Participation Not Confirmed

Update your events

Clinical trial in COVID-19 patients tests anti-inflammatory drug developed 25 years ago at Scripps Research

Contact the Supplier

Lead Product(s): IC14

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 29, 2020

Details:

The trial will assess if IC14 can temper the immune system’s response to coronavirus infection of the lungs, thus preventing dangerous levels of inflammation.

Mesoblast

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Chinaplas 2020

Participation Not Confirmed

Update your events

Mesoblast To Evaluate Anti-Inflammatory Cell Therapy Remestemcel-L

Contact the Supplier

Lead Product(s): Remestemcel-L

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 10, 2020

Details:

A clinical study conducted in China reported that allogeneic MSCs cured or significantly improved functional outcomes in all seven treated patients with severe COVID-19 pneumonia.

Biotron

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Chinaplas 2020

Participation Not Confirmed

Update your events

Biotron’s Compound BIT036 as an antiviral for COVID-19

Contact the Supplier

Lead Product(s): Cinnamoylguanidine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 07, 2020

Details:

Biotron was first to demonstrate that the E Protein within SARS is a viroporin, and has since developed compounds that inhibit viroporin activity.

Novotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Chinaplas 2020

Participation Not Confirmed

Update your events

Novotech Wins Cro Contract For Komipharm Coronavirus Covid-19 Clinical Trial In South Korea

Contact the Supplier

Lead Product(s): Panaphix

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 06, 2020

Details:

The company said it seeks to expand the use of Panaphix to cover COVID-19 treatment through this proposed clinical trial.